최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기International journal of nanomedicine, v.15, 2020년, pp.8427 - 8436
Wi, Tae In (Department of Immunology, School of Medicine, Konkuk University , Chungju 380-701 , South Korea) , Won, Ji Eun (Department of Immunology, School of Medicine, Konkuk University , Chungju 380-701 , South Korea) , Lee, Chan Mi (Department of Immunology, School of Medicine, Konkuk University , Chungju 380-701 , South Korea) , Lee, Jeong-Won (Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , South Korea) , Kang, Tae Heung (Department of Immunology, School of Medicine, Konkuk University , Chungju 380-701 , South Korea) , Shin, Byung Cheol (Bio) , Han, Hee Dong (Department of Immunology, School of Medicine, Konkuk University , Chungju 380-701 , South Korea) , Park, Yeong-Min (Department of Immunology, School of Medicine, Konku)
BackgroundEpithelial ovarian cancer (EOC) is a fatal gynecologic malignancy that is usually treated with chemotherapy after surgery. However, patients who receive chemotherapy experience severe side effects because of the inherent toxicity and high dose of chemotherapeutics. To overcome these issues...
1. Brett MR , Jennifer B. P , Thomas A. S . Epidemiology of ovarian cancer: a review . Cancer Biol Med . 2017 ; 14 ( 1 ): 9 ? 32 . doi: 10.20892/j.issn.2095-3941.2016.0084 . 28443200
2. Tsao Y , Creedy DK . Auricular acupressure: reducing side effects of chemotherapy in women with ovarian cancer . Support Care Cancer . 2019 ; 27 ( 11 ): 4155 ? 4163 . doi: 10.1007/s00520-019-04682-8 . 30796521
3. Cristea M , Han E , Salmon L , Morgan RJ . Practical considerations in ovarian cancer chemotherapy . Ther Adv Med Oncol . 2010 ; 2 ( 3 ): 175 ? 187 . doi: 10.1177/1758834010361333 . 21789133
4. Virani NA , Thavathiru E , McKernan P , Moore K , Benbrook DM , Harrison RG . Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer . Cancer Lett . 2018 ; 425 : 174 ? 182 . doi: 10.1016/j.canlet.2018.03.027 . 29574275
5. Yahara K , Ohguri T , Imada H , et al. Epithelial ovarian cancer: definitive radiotherapy for limited recurrence after complete remission had been achieved with aggressive front-line therapy . J Radiat Res . 2013 ; 54 ( 2 ): 322 ? 329 . doi: 10.1093/jrr/rrs108 . 23179378
6. Hu J , Shen Y , Zhang G , et al. Effect of acupoint therapies on chemotherapy-induced nausea and vomiting: A systematic review protocol . Medicine . 2019 ; 98 ( 37 ): e17109 . doi: 10.1097/md.0000000000017109 . 31517844
7. Ruggeri C , Gioffre S , Achilli F , Colombo GI , D’Alessandra Y . Role of microRNAs in doxorubicin-induced cardiotoxicity: an overview of preclinical models and cancer patients . Heart Fail Rev . 2018 ; 23 ( 1 ): 109 ? 122 . doi: 10.1007/s10741-017-9653-0 . 28944400
8. Jung SH , Kim SK , Jung SH , et al. Increased stability in plasma and enhanced cellular uptake of thermally denatured albumin-coated liposomes . Colloids Surf B Biointerfaces . 2010 ; 76 ( 2 ): 434 ? 440 . doi: 10.1016/j.colsurfb.2009.12.002 . 20036109
9. Krauss AC , Gao X , Li L , et al. FDA approval summary: (Daunorubicin and Cytarabine) liposome for injection for the treatment of adults with high-risk acute myeloid leukemia . Clin Cancer Res . 2019 ; 25 ( 9 ): 2685 ? 2690 . doi: 10.1158/1078-0432.ccr-18-2990 . 30541745
10. Barenholz Y . Doxil ® ― the first FDA-approved nano-drug: lessons learned . J Control Release . 2012 ; 160 ( 2 ): 117 ? 134 . doi: 10.1016/j.jconrel.2012.03.020 . 22484195
11. Pistollato F , Calderon Iglesias R , Ruiz R , et al. The use of natural compounds for the targeting and chemoprevention of ovarian cancer . Cancer Lett . 2017 ; 411 : 191 ? 200 . doi: 10.1016/j.canlet.2017.09.050 . 29017913
12. Rajesh E , Sankari LS , Malathi L , Krupaa JR . Naturally occurring products in cancer therapy . J Pharm Bioallied Sci . 2015 ; 7 ( Suppl 1 ): S181 ? 183 . doi: 10.4103/0975-7406.155895 . 26015704
13. Wei X , Shamrakov D , Nudelman S , et al. Cardinal role of intraliposome doxorubicin-sulfate nanorod crystal in doxil properties and performance . ACS Omega . 2018 ; 3 ( 3 ): 2508 ? 2517 . doi: 10.1021/acsomega.7b01235 . 30023837
14. Iwasaki K , Zheng YW , Murata S , et al. Anticancer effect of linalool via cancer-specific hydroxyl radical generation in human colon cancer . World J Gastroenterol . 2016 ; 22 ( 44 ): 9765 ? 9774 . doi: 10.3748/wjg.v22.i44.9765 . 27956800
15. Pereira I , Severino P , Santos AC , Silva AM , Souto EB . Linalool bioactive properties and potential applicability in drug delivery systems . Colloids Surf B Biointerfaces . 2018 ; 171 : 566 ? 578 . doi: 10.1016/j.colsurfb.2018.08.001 . 30098535
16. Kalepu S , Nekkanti V . Insoluble drug delivery strategies: review of recent advances and business prospects . Acta Pharm Sin B . 2015 ; 5 ( 5 ): 442 ? 453 . doi: 10.1016/j.apsb.2015.07.003 . 26579474
17. Han HD , Cho YJ , Cho SK , et al. Linalool-incorporated nanoparticles as a novel anticancer agent for epithelial ovarian carcinoma . Mol Cancer Ther . 2016 ; 15 ( 4 ): 618 ? 627 . doi: 10.1158/1535-7163.mct-15-0733-t . 26861249
18. Desale SS , Soni KS , Romanova S , Cohen SM , Bronich TK . Targeted delivery of platinum-taxane combination therapy in ovarian cancer . J Control Release . 2015 ; 220 ( Pt B ): 651 ? 659 . doi: 10.1016/j.jconrel.2015.09.007 . 26381902
19. Bayat Mokhtari R , Homayouni TS , Baluch N , et al. Combination therapy in combating cancer . Oncotarget . 2017 ; 8 ( 23 ): 38022 ? 38043 . doi: 10.18632/oncotarget.16723 . 28410237
20. Pritchard JR , Bruno PM , Gilbert LA , Capron KL , Lauffenburger DA , Hemann MT . Defining principles of combination drug mechanisms of action . Proc Natl Acad Sci U S A . 2013 ; 110 ( 2 ): E170 ? 179 . doi: 10.1073/pnas.1210419110 . 23251029
21. Kang Y , Hu W , Ivan C , et al. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer . J Natl Cancer Inst . 2013 ; 105 ( 19 ): 1485 ? 1495 . doi: 10.1093/jnci/djt210 . 24062525
22. Lu C , Han HD , Mangala LS , et al. Regulation of tumor angiogenesis by EZH2 . Cancer Cell . 2010 ; 18 ( 2 ): 185 ? 197 . doi: 10.1016/j.ccr.2010.06.016 . 20708159
23. Byeon Y , Lee JW , Choi WS , et al. CD44-targeted PLGA nanoparticles incorporating paclitaxel and FAK siRNA overcome chemoresistance in epithelial ovarian cancer . Cancer Res . 2018 ; 78 ( 21 ): 6247 . doi: 10.1158/0008-5472.can-17-3871 . 30115698
24. Kwon HJ , Byeon Y , Jeon HN , Cho SH , Han HD , Shin BC . Gold cluster-labeled thermosensitive liposmes enhance triggered drug release in the tumor microenvironment by a photothermal effect . J Control Release . 2015 ; 216 : 132 ? 139 . doi: 10.1016/j.jconrel.2015.08.002 . 26247553
25. Han HD , Jeon YW , Kwon HJ , et al. Therapeutic efficacy of doxorubicin delivery by a CO2 generating liposomal platform in breast carcinoma . Acta Biomater . 2015 ; 24 : 279 ? 285 . doi: 10.1016/j.actbio.2015.06.019 . 26102337
26. Won JE , Byeon Y , Wi TI , et al. Enhanced antitumor immunity using a tumor cell lysate-encapsulated CO2-generating liposomal carrier system and photothermal irradiation . ACS Appl Bio Mater . 2019 ; 2 ( 6 ): 2481 ? 2489 . doi: 10.1021/acsabm.9b00183 .
27. Ou Y-C , Wen X , Johnson CA , et al. Multimodal multiplexed immunoimaging with nanostars to detect multiple immunomarkers and monitor response to immunotherapies . ACS Nano . 2020 ; 14 ( 1 ): 651 ? 663 . doi: 10.1021/acsnano.9b07326 . 31851488
28. Mayer LP , Dyer CA , Eastgard RL , Hoyer PB , Banka CL . Atherosclerotic lesion development in a novel ovary-intact mouse model of perimenopause . Arterioscler Thromb Vasc Biol . 2005 ; 25 ( 9 ): 1910 ? 1916 . doi: 10.1161/01.ATV.0000175767.46520.6a . 15994440
29. Cortez AJ , Tudrej P , Kujawa KA , Lisowska KM . Advances in ovarian cancer therapy . Cancer Chemother Pharmacol . 2018 ; 81 ( 1 ): 17 ? 38 . doi: 10.1007/s00280-017-3501-8 . 29249039
30. Chamberlin SR , Blucher A , Wu G , et al. Natural product target network reveals potential for cancer combination therapies . Front Pharmacol . 2019 ; 10 : 557 . doi: 10.3389/fphar.2019.00557 . 31214023
31. Golombek SK , May J-N , Theek B , et al. Tumor targeting via EPR: strategies to enhance patient responses . Adv Drug Deliv Rev . 2018 ; 130 : 17 ? 38 . doi: 10.1016/j.addr.2018.07.007 . 30009886
32. Sun R , Liu Y , Li S-Y , et al. Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells . Biomaterials . 2015 ; 37 : 405 ? 414 . doi: 10.1016/j.biomaterials.2014.10.018 . 25453968
33. Barui S , Saha S , Mondal G , Haseena S , Chaudhuri A . Simultaneous delivery of doxorubicin and curcumin encapsulated in liposomes of pegylated RGDK-lipopeptide to tumor vasculature . Biomaterials . 2014 ; 35 ( 5 ): 1643 ? 1656 . doi: 10.1016/j.biomaterials.2013.10.074 . 24239109
해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.